Bristol-Myers Squibb Foundation's Together on Diabetes™ Marks World Diabetes Day with Second Annual
Bristol-Myers Squibb Foundation's Together on Diabetes™Marks World Diabetes Day with Second Annual Report and Two New Grants in India
NEW YORK--(BUSINESS WIRE)-- The Bristol-Myers Squibb Foundation today marked World Diabetes Day and the second anniversary of its Together on Diabetes™ initiative by issuing the initiative's second annual report and awarding two new grants to partners in India.
In its first two years, Together on Diabetes has awarded $43.2 million to 21 grantees working in 28 states and more than 50 communities in the United States. Since the expansion of the initiative to China and India in May 2012, $3.37 million has been awarded for seven projects in those countries. China, India and the U.S. have the most people living with diabetes.
"We are enormously proud of the work of our Together on Diabetes grantees and partners," said John Damonti, president, Bristol-Myers Squibb Foundation. "They are engendering hope in those hardest hit by the diabetes epidemic and transforming communities so that the healthy choice is an easier choice for the person living with type 2 diabetes."
Together on Diabetes' second annual report provides an update on the Foundation's grantmaking and profiles how the innovative projects are helping people living with diabetes to improve control of their disease and how communities are coming together to make diabetes information and supportive services more visible, accessible, navigable, culturally competent and integrated with clinical care. The report also captures initial results and early lessons from the projects.
Two new Together on Diabetes grants in India support programs in Jodhpur and Mumbai:
- Humana People to People will receive US $355,991 over two years to reduce diabetes-related morbidity and mortality and prevent the onset of type 2 diabetes among those at increased risk for the disease through timely intervention and home-based diabetes care.
- United Way Mumbai Helpline will receive US $205,362 over two years to use community-based lifestyle interventions for the prevention, early detection and management of type 2 diabetes among working adults and municipal and public school workers in Mumbai.
About Together on Diabetes
Together on Diabetes is a five-year, $115 million initiative launched in November 2010 by the Bristol-Myers Squibb Foundation to improve health outcomes of people living with type 2 diabetes in China, India and the United States by strengthening patient self-management education, community-based supportive services and broad-based community mobilization. Consistent with the Bristol-Myers Squibb Foundation's mission to reduce health disparities, this initiative targets adult populations disproportionately affected by the disease.
You can learn more about Together on Diabetes and view the annual report at www.TogetherOnDiabetes.com. To view an interactive map showing the location and project details of the Together on Diabetes project sites in the U.S., go to www.bms.com/togetherondiabetes/partners/Pages/partners-map.aspx.
About the Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious disease. For more information about the Bristol-Myers Squibb Foundation, please visit www.bms.com/foundation.
Frederick J. Egenolf, 609-252-4875
KEYWORDS: United States Asia Pacific North America New York India
The article Bristol-Myers Squibb Foundation's Together on Diabetes™ Marks World Diabetes Day with Second Annual Report and Two New Grants in India originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.